Highlights Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Real-time BOERSE MUENCHEN Other stock markets 01:13:33 09/07/2024 am IST			5-day change	1st Jan Change
15.9 ^EUR	0.00%		-1.85%	-34.84%

27/06	Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	MT
20/06	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	04/06	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24/05	MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22/05	MT
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05	CI
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20/05	MT
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05	CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16/05	MT
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14/05	MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	14/05	CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	13/05	MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	13/05	MT
Zai Lab's Cancer Drug Gets NDA Approval in China	13/05	MT
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA	13/05	CI
Zai Lab's Shares Rise After Q1 Beat	09/05	MT
Top Premarket Gainers	09/05	MT
Zai Lab Q1 Loss Widens Despite Higher Revenue	09/05	MT
Zai Lab Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher	03/05	MT
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint	01/04	MT
Zai Lab Reports Lesser Loss in 2023	28/03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Highlights

Filters